Recent news on Zavesca

Actelion announces first quarter results 2007  -  Apr 19, 2007
PharmaLive.com (press release),In the first quarter of 2007, Zavesca® sales reached CHF 7.5 million (Q1 2006: CHF 5.4 m). On a quarter-to-quarter basis, Zavesca® sales were flat (Q4 2006:

Stem cells have multiple brain benefits  -  Mar 12, 2007
DrugResearcher.com,Zavesca (miglustat) is now marketed by Actelion and is approved to treat Gaucher's disease - another disease caused by the build up of lipids.

Actelion "overweight," target price raised  -  Feb 26, 2007
newratings.comPAH and Zavesca businesses and the multi-billion dollar potential of the company’s four products, Tracleer, orexin-RA, renin inhibitor and S1P1.

Local boy will be special guest of O's  -  Feb 25, 2007
Frederick News Post (subscription),He does take an experimental drug called Zavesca twice a day. It tastes terrible and can cause tremors and stomach problems.

Actelion Announces Full Year 2006 Financial Results  -  Feb 21, 2007
Primenewswire (press release),I expect that Tracleer(r), Ventavis(r) and Zavesca(r) will continue to grow in the coming years, as the result of the favorable characteristics each

Net income almost doubles at Switzerland's Actelion  -  Feb 22, 2007
Pharma Times (subscription),Also contributing to Actelion's coffers was Zavesca (miglustat), its new treatment for Gaucher disease, which brought in 25.4 million francs,

Panacos Appoints Dr. Tom Lategan, Vice President of Regulatory Affairs  -  Feb 14, 2007
Business Wire (press release),Also at Actelion, he drove the approval of ZAVESCA in the US after an unsuccessful application by a previous sponsor. Prior to Actelion, Dr. Lategan was

Panacos Reports Fourth Quarter and Full Year 2006 Financial Results  -  Feb 21, 2007
Business Wire (press release),Dr. Lategan was instrumental in the regulatory approvals of several drugs, including TRACLEER, ZAVESCA, and ANGIOMAX and was previously Vice President,

Actelion Announces Full Year 2006 Financial Results  -  Feb 22, 2007
PharmaLive.com (press release),I expect that Tracleer®, Ventavis® and Zavesca® will continue to grow in the coming years, as the result of the favorable characteristics each medication

Male contraception: One door opens, another closes  Nov 7, 2006
The latest promising contraceptive that didn't make the leap from mice to men is miglustat (trade name Zavesca) (Human Reproduction, Oct. 25). ... -Biology News Net (press release), Actelion Announces 9-Month Results for 2006  Oct 18, 2006
Zavesca(r) sales in the approved indication type 1 Gaucher disease contributed in the first nine months of 2006 CHF 18.0 million (9 months 2005: CHF 9.8 m). On ... -PrimeZone (press release), Male Contraception: Are We Getting Close?  -  Nov 17, 2006
Keep the Doctor Away,The latest promising contraceptive that didn't make the leap from mice to men is miglustat (trade name Zavesca). The drug is already approved and on the

At All Costs  Aug 8, 2006
But now, "that's gone," she said in July. That was when Emily had had just less than a month on Zavesca, an experimental drug the family buys. ... -Modesto Bee

Actelion Announces Half Year Financial Results 2006  Jul 19, 2006
Zavesca(r) sales contributed in the first half of 2006 CHF 11.6 million to Actelion's revenue (H1 2005: CHF 5.8 m). On a quarter-to-quarter basis, Zavesca(r ... -PrimeZone

UPDATE: Actelion 2Q Net Profit Soars On Tracleer Sales  Jul 19, 2006
5 million from CHF149.9 million in the same quarter a year ago, helped by stronger sales for Actelion's second product on the market, Zavesca, a treatment for ... -Easy Bourse (Communiqués de presse)



(PZ) Actelion Announces First Quarter Results 2006  Apr 19, 2006
In the first quarter of 2006, Zavesca(r) sales reached CHF 5.4 million (Q1 2005: CHF 2.4 m). On a quarter-to-quarter basis, Zavesca(r) sales increased by 17 ... - Houston Chronicle





Actelion Announces Full Year 2005 Financial Results  Feb 23, 2006
...net revenue increased to CHF 663.6 million (2004: 471.9 m), including Tracleer® sales revenue of CHF 633.2 million (2004: 449.2 m), Zavesca® sales revenue of ... - PharmaLive.com,

Argenta Discovery Strenthens Senior Management Team as Respiratory ...  Feb 22, 2006
In the latter capacity he established the development function and built the team that took the Gaucher disease therapy Zavesca from first dose in patients ... - PharmaLive.com,

Bear Stearns Resumes Actelion At Peer Perform  Jan 27, 2006
Actelion's wildcards Zavesca, Clazosentan and Actelion-1 could lead to earnings upgrades. Sets fair value at CHF110. Shares +0.4% at CHF113.50. (KAB). ... - New Ratings

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional